Ocugen Inc (OCGN)

$1.24 +0.03 (2.48%)
Market Cap 362.29M
Revenue (ttm) 4.06M
Net Income (ttm) -54.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,331.28%
Debt to Equity Ratio 8.05
Volume 3,243,806
Avg Vol 4,878,340
Day's Range N/A - N/A
Shares Out 312.32M
Stochastic %K 71%
Beta 4.54
Analysts Strong Sell
Price Target $7.50

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
AvengerTrader
AvengerTrader Dec. 4 at 9:18 PM
What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. Watching: $PSKY $VTGN $OCGN $ARBK as well
0 · Reply
Milanfinest
Milanfinest Dec. 4 at 9:02 PM
$OCGN my fav retard stock since always🤣❤️
0 · Reply
Pit1908
Pit1908 Dec. 4 at 9:01 PM
$OCGN 🌍🌏🌎👀 https://youtu.be/9quXTbPV5gA?si=ZWtZYi9ro3rUhkkN
0 · Reply
Planetpaprika
Planetpaprika Dec. 4 at 8:44 PM
$OCGN 's presentation/chat was yesterday... https://www.msn.com/en-us/money/companies/ocugen-ceo-to-spotlight-gene-therapy-breakthroughs-at-high-profile-growth-conference/ar-AA1Rbcge?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1
0 · Reply
Jag2441
Jag2441 Dec. 4 at 8:36 PM
$OCGN Yep, currently in algorithm hell.
0 · Reply
BrunoMonteiro
BrunoMonteiro Dec. 4 at 8:09 PM
$OCGN Algos holding the range again. Tight box between 1.228–1.240. Compression = breakout setup. Above 1.248 we run to 1.26–1.28. Still bullish. 🚀
0 · Reply
SGimvesting
SGimvesting Dec. 4 at 8:05 PM
$OCGN 🚀
0 · Reply
BeMaWe
BeMaWe Dec. 4 at 7:54 PM
$OCGN
0 · Reply
3I_ATLAS
3I_ATLAS Dec. 4 at 7:18 PM
$OCGN here I'll sell a little now for profit and it will jump 1.28 close. never fails
0 · Reply
Nakayama
Nakayama Dec. 4 at 6:53 PM
$OCGN dam yall ain’t go nowhere 🩸🩸🩸🩸🩸🩸
0 · Reply
Latest News on OCGN
Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 14 days ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:21 PM EST - 4 weeks ago

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 4 weeks ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 6 weeks ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen: A Retinal Disease Juggernaut In The Making

Sep 23, 2025, 11:11 AM EDT - 2 months ago

Ocugen: A Retinal Disease Juggernaut In The Making

Why Ocugen Stock Zoomed 12% Higher Today

Sep 15, 2025, 7:04 PM EDT - 2 months ago

Why Ocugen Stock Zoomed 12% Higher Today

Ocugen Shares Are Trading Higher Monday: What's Going On?

Sep 15, 2025, 4:29 PM EDT - 2 months ago

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 2 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 3 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 4 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 4 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 4 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen (OCGN) Q2 Revenue Jumps 20%

Aug 1, 2025, 7:16 PM EDT - 4 months ago

Ocugen (OCGN) Q2 Revenue Jumps 20%

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 12:30 PM EDT - 4 months ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 4 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 4 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 4 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 5 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 5 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18, 2025, 4:00 PM EDT - 6 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 6 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 6 months ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 6 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 6 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:02 AM EDT - 7 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 7 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 7 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 8 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 9 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 9 months ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 9 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 10 months ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 10 months ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 10 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 10 months ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 11 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 11 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Jan 13, 2025, 6:30 AM EST - 11 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 19, 2024, 6:38 AM EST - 1 year ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 11, 2024, 7:02 AM EST - 1 year ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 27, 2024, 7:09 AM EST - 1 year ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 20, 2024, 7:30 AM EST - 1 year ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 19, 2024, 7:02 AM EST - 1 year ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 10:18 AM EST - 1 year ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 8, 2024, 6:45 AM EST - 1 year ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding

Nov 7, 2024, 6:30 AM EST - 1 year ago

Ocugen Secures $30 Million in Debt Funding

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 28, 2024, 6:30 AM EDT - 1 year ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 22, 2024, 7:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 17, 2024, 7:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

AvengerTrader
AvengerTrader Dec. 4 at 9:18 PM
What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. Watching: $PSKY $VTGN $OCGN $ARBK as well
0 · Reply
Milanfinest
Milanfinest Dec. 4 at 9:02 PM
$OCGN my fav retard stock since always🤣❤️
0 · Reply
Pit1908
Pit1908 Dec. 4 at 9:01 PM
$OCGN 🌍🌏🌎👀 https://youtu.be/9quXTbPV5gA?si=ZWtZYi9ro3rUhkkN
0 · Reply
Planetpaprika
Planetpaprika Dec. 4 at 8:44 PM
$OCGN 's presentation/chat was yesterday... https://www.msn.com/en-us/money/companies/ocugen-ceo-to-spotlight-gene-therapy-breakthroughs-at-high-profile-growth-conference/ar-AA1Rbcge?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1
0 · Reply
Jag2441
Jag2441 Dec. 4 at 8:36 PM
$OCGN Yep, currently in algorithm hell.
0 · Reply
BrunoMonteiro
BrunoMonteiro Dec. 4 at 8:09 PM
$OCGN Algos holding the range again. Tight box between 1.228–1.240. Compression = breakout setup. Above 1.248 we run to 1.26–1.28. Still bullish. 🚀
0 · Reply
SGimvesting
SGimvesting Dec. 4 at 8:05 PM
$OCGN 🚀
0 · Reply
BeMaWe
BeMaWe Dec. 4 at 7:54 PM
$OCGN
0 · Reply
3I_ATLAS
3I_ATLAS Dec. 4 at 7:18 PM
$OCGN here I'll sell a little now for profit and it will jump 1.28 close. never fails
0 · Reply
Nakayama
Nakayama Dec. 4 at 6:53 PM
$OCGN dam yall ain’t go nowhere 🩸🩸🩸🩸🩸🩸
0 · Reply
SiejeUGA
SiejeUGA Dec. 4 at 6:32 PM
$OCGN
0 · Reply
Pit1908
Pit1908 Dec. 4 at 6:06 PM
$OCGN The tattoo will be legend! 💪🏻
3 · Reply
Djtrush
Djtrush Dec. 4 at 5:40 PM
$OCGN 1.
1 · Reply
SamTheDog
SamTheDog Dec. 4 at 5:10 PM
$OCGN Fingers crossed we're moving into another consistent rise like we saw in September/October, only this time with a higher and sustainable highs .
1 · Reply
3I_ATLAS
3I_ATLAS Dec. 4 at 5:10 PM
$OCGN bounce that thaaang
0 · Reply
Ostocks339
Ostocks339 Dec. 4 at 4:52 PM
$OCGN So many idiots want instant gratification these days. Iphones ruined the meaning of patience. Investment. Look up the meaning.
0 · Reply
Chino43101
Chino43101 Dec. 4 at 4:45 PM
$OCGN still have that 1.07 gap?
0 · Reply
Dt4436
Dt4436 Dec. 4 at 4:43 PM
$OCGN Shankar out there flirting and making Deals!🤝🏼🚀🚀🚀
0 · Reply
Bond_James_Bond000
Bond_James_Bond000 Dec. 4 at 4:26 PM
$OCGN bla submission is around the corner 🏛️ 2026 is looking 👌
0 · Reply
Dfwmb
Dfwmb Dec. 4 at 4:14 PM
$OCGN having your CEO quoted in a Senatorial announcement could be considered news.
0 · Reply
3I_ATLAS
3I_ATLAS Dec. 4 at 4:13 PM
$OCGN
0 · Reply
AnchorMB
AnchorMB Dec. 4 at 4:10 PM
$OCGN love when this goes up on zero news day and just because .....
0 · Reply